Home ETF List About

Portfolio Holdings Detail for ISIN IE00BF4RFH31
Stock Name / FundiShares MSCI World Small Cap UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares III Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300PZLRJB7M8H1057
ETF TickerWSML(USD) LSE
ETF TickerWLDS(GBP) LSE
ETF TickerIUSN(EUR) F
ETF TickerIUSN.DE(EUR) CXE
ETF TickerWLDS.LS(GBP) CXE
ETF TickerWSML.LS(USD) CXE
ETF TickerWSML.L(GBP) LSE
ETF TickerWLDS.L(GBP) LSE

Holdings detail for RYTM

Stock NameRhythm Pharmaceuticals Inc
TickerRYTM(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS76243J1051
LEI529900JPNWXQ8DPLA551

Show aggregate RYTM holdings

News associated with RYTM

FDA Accepts Rhythm Pharma' SNDA For Setmelanotide To Treat Acquired Hypothalamic Obesity
(RTTNews) - Rhythm Pharmaceuticals, Inc. (RYTM) announced that the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application or sNDA for setmelanotide seeking approval for the treatment of conditions associated with acquired hypotha - 2025-08-20 22:52:50
Chicago Partners Investment Group LLC Sells 186 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Chicago Partners Investment Group LLC reduced its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 5.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 3,510 shares of the company’s stock after selling 186 shares during the period. Chicago Partners Investment Group LLC’s holdings […] - 2025-08-13 05:18:50
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $91.93
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned an average rating of “Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among analysts […] - 2025-08-04 02:26:49
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Holdings Lifted by Victory Capital Management Inc.
Victory Capital Management Inc. lifted its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,326 shares of the company’s stock after acquiring an additional 174 shares during the […] - 2025-08-01 05:01:17
Wall Street Zen Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to “Hold”
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. RYTM has been the subject of several other reports. Oppenheimer boosted their target price on Rhythm Pharmaceuticals from $76.00 to $110.00 and gave the company an […] - 2025-07-28 04:00:47
Bank of New York Mellon Corp Sells 1,661 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Bank of New York Mellon Corp reduced its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.1% in the first quarter, HoldingsChannel reports. The firm owned 146,585 shares of the company’s stock after selling 1,661 shares during the period. Bank of New York Mellon Corp’s holdings in Rhythm Pharmaceuticals were worth $7,765,000 at […] - 2025-07-23 04:34:46
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) had its price objective lifted by Canaccord Genuity Group from $92.00 to $105.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would suggest a potential upside of 17.71% from the stock’s current price. Several […] - 2025-07-20 05:22:52
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells $308,222.75 in Stock
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) CAO Christopher Paul German sold 3,817 shares of Rhythm Pharmaceuticals stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $80.75, for a total transaction of $308,222.75. Following the transaction, the chief accounting officer directly owned 922 shares of the […] - 2025-07-14 06:10:46
Rhythm Pharmaceuticals (NASDAQ:RYTM) Hits New 12-Month High Following Analyst Upgrade
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Thursday after Oppenheimer raised their price target on the stock from $76.00 to $110.00. Oppenheimer currently has an outperform rating on the stock. Rhythm Pharmaceuticals traded as high as $89.05 and last traded at $89.00, with […] - 2025-07-11 02:50:53
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Analyst Upgrade
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s share price gapped up prior to trading on Wednesday after Needham & Company LLC raised their price target on the stock from $72.00 to $95.00. The stock had previously closed at $65.14, but opened at $76.75. Needham & Company LLC currently has a buy rating on the […] - 2025-07-10 02:19:11
Wednesday's ETF Movers: XBI, COPX
In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 2.7% on the day. Components of that ETF showing particular strength include shares of Rhythm Pharmaceuticals, up about 31.3% and shares of Capricor Therapeutics, up about 12.3% on the da - 2025-07-09 13:28:39
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of “Buy” by Brokerages
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned an average rating of “Buy” from the thirteen research firms that are presently covering the firm, MarketBeat.com reports. Thirteen equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on the stock […] - 2025-07-07 03:16:56
Avior Wealth Management LLC Acquires Shares of 4,589 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Avior Wealth Management LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 4,589 shares of the company’s stock, valued at approximately $243,000. Several other institutional investors and hedge funds have also bought and sold shares of the business. Assenagon Asset […] - 2025-06-24 04:52:55
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Recommendation of “Buy” from Analysts
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has received a consensus recommendation of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat.com reports. Thirteen investment analysts have rated the stock with a buy rating. The average 12 month price objective among analysts that have updated their coverage on the stock in […] - 2025-06-12 04:56:54
Analysts Forecast 16% Upside For The Holdings of SMLF
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:51:20
Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 76,084 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 76,084 shares of the company’s stock, valued at approximately $4,259,000. A number of other hedge funds and other institutional investors have also added to or reduced their […] - 2025-06-02 05:36:58
Nuveen Asset Management LLC Sells 972 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Nuveen Asset Management LLC decreased its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 0.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 146,903 shares of the company’s stock after selling 972 shares during […] - 2025-05-29 05:36:56
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,156 shares of the company’s stock after buying an additional 654 shares during […] - 2025-05-23 05:32:53
Analysts Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $75.38
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. Thirteen analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on […] - 2025-05-23 04:30:49
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Purchased by BNP Paribas Financial Markets
BNP Paribas Financial Markets boosted its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 491.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 85,249 shares of the company’s stock after purchasing an additional 70,824 shares during the period. BNP […] - 2025-05-14 06:42:59
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Comerica Bank
Comerica Bank lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 2.5% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 17,113 shares of the company’s stock after selling 447 shares during the period. Comerica Bank’s holdings in Rhythm Pharmaceuticals were worth $958,000 as of its most recent filing with the […] - 2025-05-13 06:00:54
Stifel Financial Corp Has $1.09 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Stifel Financial Corp decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,516 shares of the company’s stock after selling 326 shares during the quarter. Stifel Financial Corp’s holdings in […] - 2025-05-09 05:27:01
First Trust Advisors LP Has $6.63 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
First Trust Advisors LP grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 67.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 118,337 shares of the company’s stock after buying an additional 47,575 shares during the period. First Trust Advisors LP owned 0.19% of […] - 2025-04-30 06:01:00
Legal & General Group Plc Reduces Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Legal & General Group Plc decreased its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 7.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,803 shares of the company’s stock after selling 4,244 shares during the period. Legal & General […] - 2025-04-24 05:07:03
Invesco Ltd. Has $16.95 Million Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Invesco Ltd. grew its position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by 14.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 302,846 shares of the company’s stock after purchasing an additional 38,429 shares during the period. Invesco Ltd.’s holdings in Rhythm Pharmaceuticals were worth $16,953,000 at the end of the […] - 2025-04-21 04:44:46
Trexquant Investment LP Takes $437,000 Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Trexquant Investment LP bought a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor bought 7,798 shares of the company’s stock, valued at approximately $437,000. A number of other large investors have also recently added to or reduced their stakes in RYTM. SRS Capital Advisors […] - 2025-04-13 05:31:02
Rhythm Pharmaceuticals (NASDAQ:RYTM) Raised to Buy at Bank of America
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Monday, MarketBeat.com reports. The firm presently has a $63.00 price objective on the stock. Bank of America‘s price objective points to a […] - 2025-04-09 02:52:50
Norges Bank Acquires New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Norges Bank bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 205,649 shares of the company’s stock, valued at approximately $11,512,000. Norges Bank owned approximately 0.33% […] - 2025-04-08 04:48:51
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its price target upped by Wells Fargo & Company from $80.00 to $91.00 in a research note published on Monday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock. A number of other research firms have also recently issued reports on RYTM. Morgan Stanley restated […] - 2025-04-08 02:52:50
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up After Analyst Upgrade
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report)’s stock price gapped up before the market opened on Monday after Wells Fargo & Company raised their price target on the stock from $80.00 to $91.00. The stock had previously closed at $46.95, but opened at $48.33. Wells Fargo & Company currently has an overweight rating on […] - 2025-04-08 02:12:52

iShares MSCI World Small Cap UCITS ETF USD (Acc) RYTM holdings

DateNumber of RYTM Shares HeldBase Market Value of RYTM SharesLocal Market Value of RYTM SharesChange in RYTM Shares HeldChange in RYTM Base ValueCurrent Price per RYTM Share HeldPrevious Price per RYTM Share Held
2025-10-15 (Wednesday)37,039USD 4,050,215USD 4,050,215
2025-10-10 (Friday)36,817USD 3,711,890USD 3,711,890
2025-10-08 (Wednesday)36,817USD 3,690,168USD 3,690,168
2025-10-07 (Tuesday)36,817RYTM holding increased by 148USD 3,675,441RYTM holding increased by 87013USD 3,675,441148USD 87,013 USD 99.83 USD 97.86
2025-10-06 (Monday)36,669USD 3,588,428RYTM holding decreased by -42536USD 3,588,4280USD -42,536 USD 97.86 USD 99.02
2025-10-03 (Friday)36,669USD 3,630,964RYTM holding increased by 65637USD 3,630,9640USD 65,637 USD 99.02 USD 97.23
2025-10-02 (Thursday)36,669USD 3,565,327RYTM holding decreased by -101940USD 3,565,3270USD -101,940 USD 97.23 USD 100.01
2025-10-01 (Wednesday)36,669USD 3,667,267RYTM holding decreased by -35935USD 3,667,2670USD -35,935 USD 100.01 USD 100.99
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of RYTM by Blackrock for IE00BF4RFH31

Show aggregate share trades of RYTM

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-07BUY148 99.830* 64.09
2025-09-08SELL-296 99.770* 62.03 Profit of 18,360 on sale
2025-08-15BUY134 97.610* 61.82
2025-08-07BUY402 92.480* 61.41
2025-07-29BUY134 85.630* 60.44
2025-07-14BUY268 89.150* 59.13
2025-06-30BUY272 63.190* 58.36
2025-06-25BUY408 62.290* 58.28
2025-06-20SELL-68 61.990* 58.19 Profit of 3,957 on sale
2025-06-12SELL-544 63.020* 58.01 Profit of 31,558 on sale
2025-06-02BUY204 63.660* 57.51
2025-05-28BUY136 59.590* 57.43
2025-05-14BUY68 57.280* 57.11
2025-05-13BUY136 56.790* 57.11
2025-05-07BUY204 64.630* 56.99
2025-04-28BUY68 64.410* 56.48
2025-04-16BUY884 61.340* 56.06
2025-04-14BUY136 60.140* 55.95
2025-04-08SELL-136 57.730* 55.82 Profit of 7,591 on sale
2025-04-04SELL-138 46.950* 55.93 Profit of 7,718 on sale
2025-03-28BUY680 54.800* 56.10
2025-03-12SELL-138 51.320* 56.69 Profit of 7,823 on sale
2025-03-04SELL-136 53.220* 57.12 Profit of 7,768 on sale
2025-02-28SELL-4,510 54.910* 57.23 Profit of 258,119 on sale
2025-02-26SELL-316 53.320* 57.37 Profit of 18,128 on sale
2025-02-13BUY79 57.560* 57.57
2025-02-12BUY316 57.640* 57.57
2025-01-27BUY79 56.520* 57.20
2025-01-23BUY78 58.470* 57.15
2024-12-09BUY2,844 57.410* 57.12
2024-12-04BUY158 60.370* 56.92
2024-12-03BUY237 60.080* 56.81
2024-11-25SELL-1,494 59.920* 55.52 Profit of 82,945 on sale
2024-11-19BUY498 59.970* 54.62
2024-11-18BUY166 58.500* 54.39
2024-11-12BUY328 64.060* 53.78
2024-11-11BUY82 65.580* 53.00
2024-11-07BUY410 63.900* 51.06
2024-10-23BUY164 49.020* 49.66
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of RYTM

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1957,7580112,12451.5%
2025-09-1879,8290132,26760.4%
2025-09-1794,8110142,28166.6%
2025-09-1669,29420105,41865.7%
2025-09-1549,993495130,67538.3%
2025-09-1291,089428207,39843.9%
2025-09-11102,9764,654284,27736.2%
2025-09-10112,3345,431192,88758.2%
2025-09-0981,3160146,46755.5%
2025-09-08107,0710320,02633.5%
2025-09-0585,28221165,03251.7%
2025-09-0463,0341,268179,40635.1%
2025-09-0393,8564,725232,51740.4%
2025-09-02118,6501,127276,51542.9%
2025-08-2952,45933140,59437.3%
2025-08-2888,661500177,30150.0%
2025-08-2734,3700144,19823.8%
2025-08-2635,8953,580182,87719.6%
2025-08-2552,3220141,15037.1%
2025-08-22134,2853,024254,45152.8%
2025-08-21237,643249345,61868.8%
2025-08-20158,6851,343190,44983.3%
2025-08-1959,92517894,09263.7%
2025-08-1874,0303,694131,50656.3%
2025-08-1567,4484,106159,63542.3%
2025-08-1482,22850225,05436.5%
2025-08-13118,4926,021264,48344.8%
2025-08-1277,184326156,47949.3%
2025-08-11104,4521,770229,18145.6%
2025-08-08104,6203,964349,55229.9%
2025-08-07118,63422,554179,49866.1%
2025-08-06128,9260232,03455.6%
2025-08-05150,641988242,99862.0%
2025-08-04113,562539192,79058.9%
2025-08-01162,238522245,73666.0%
2025-07-31107,0600186,42657.4%
2025-07-3074,13323152,13548.7%
2025-07-2984,977139138,58461.3%
2025-07-2890,1653232,09738.8%
2025-07-2566,761574128,31052.0%
2025-07-2466,075215173,15038.2%
2025-07-23113,2810215,58752.5%
2025-07-2296,0670222,05943.3%
2025-07-2178,36017228,06834.4%
2025-07-1867,969252244,27127.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.